<i>In silico</i> and pharmacological characterization of these dual modulators led to the identification of compound <b>2o</b> as a first-in-class LIFR/GPBAR1 modulator that reverses liver fibrosis in vitro and in vivo. The gene discussed is LIFR; the disease is Hepatic fibrosis.